These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37422379)

  • 1. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Kim S; Ko M; Heo Y; Lee YK; Kwon Y; Choi SK; Bahng E
    Vaccine; 2023 Aug; 41(35):5066-5071. PubMed ID: 37422379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Kuriyama K; Murakami K; Masuda T; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2023 Jun; 41(25):3763-3771. PubMed ID: 37198021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
    Smith K; Hegazy K; Cai MR; McKnight I; Rousculp MD; Alves K
    Vaccine; 2023 Jun; 41(26):3930-3936. PubMed ID: 37211453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
    Underwood E; Dunkle LM; Madhi SA; Gay CL; Heath PT; Kotloff KL; Smith K; Chau G; Galbiati S; McGarry A; Woo W; Cho I; Alves K; Áñez G; Bennett C; Shinde V; Fries L; Mallory RM; Glenn GM; Toback S
    Expert Rev Vaccines; 2023; 22(1):501-517. PubMed ID: 37246757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax
    Kim HY; Cho JY; Yoon HJ; Choi YD; Ahn Y; Jeong MH; Cho JG; Kim KH
    J Korean Med Sci; 2022 Aug; 37(34):e265. PubMed ID: 36038960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
    Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
    Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea.
    Ko M; Kim S; Choi SK; Shin SH; Lee YK; Kwon Y
    Osong Public Health Res Perspect; 2024 Aug; 15(4):364-374. PubMed ID: 38988090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
    PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Fix J; Christopher Mast T; Smith K; Baker N
    Vaccine; 2024 Apr; 42(9):2161-2165. PubMed ID: 38494410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
    Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y
    Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea.
    Kwon Y; Hwang I; Ko M; Kim H; Kim S; Seo SY; Cho E; Lee YK
    Epidemiol Health; 2023; 45():e2023006. PubMed ID: 37183320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
    Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD;
    J Infect; 2023 Sep; 87(3):230-241. PubMed ID: 37331429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertigo and Dizziness After Coronavirus Disease-2019 Vaccination: A Nationwide Analysis.
    Kim SH; Yon DK; Choi YS; Lee J; Park KH; Lee YJ; Park DC; Kim SS; Rim HS; Yeo SG
    J Int Adv Otol; 2023 Jun; 19(3):228-233. PubMed ID: 37272641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reported rates of all-cause serious adverse events following immunization with BNT-162b in 5-17-year-old children in the United States.
    Mangat HS; Rippon B; Reddy NT; Syed AA; Maruthanal JM; Luedtke S; Puthumana JJ; Srivatsa A; Bosman A; Kostkova P
    PLoS One; 2023; 18(2):e0281993. PubMed ID: 36800368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.